Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia.
about
Development of macromolecular prodrug for rheumatoid arthritisEffects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptorInorganic arsenic and human prostate cancerPlasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats.Evaluation of Apoptotic Marker Bcl2, CD4+, Human Hepatocyte Growth Factor and Metalloproteinase-9 as Tumor Markers for Patients with Hepatocellular Carcinoma.Human prostate cancer risk factors.ERK5 signalling in prostate cancer promotes an invasive phenotype.Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinomaRegulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF).Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancerExpression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease.RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.Molecular imaging of prostate cancer: a concise synopsisRoles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.Pomegranate and its components as alternative treatment for prostate cancer.Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells.Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells.Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.Colocalisation of matrix metalloproteinase-9-mRNA and protein in human colorectal cancer stromal cells.Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis.Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells.Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3).Characteristics of a human prostate stromal cell line related to its use in a stromal-epithelial coculture model for the study of cancer chemoprevention.Inorganic arsenite-induced malignant transformation of human prostate epithelial cells.Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model.Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines.Molecular biology of prostatic intraepithelial neoplasia.Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue.Proteolysis in human breast and colorectal cancer.Ultrastructure of prostatic intraepithelial neoplasia.In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells.Altered expression of extracellular matrix and proteinases in Noble rat prostate gland after long-term treatment with sex steroids.Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis.Developmental expression of MMP-9 (gelatinase B) mRNA in mouse embryos.Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis.The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU).
P2860
Q27693332-852AD41A-BA3B-4CA2-822B-9CB654FD590AQ28343691-B17577CB-7B04-49D5-8751-A85936BFFD13Q28383469-7A74EFB8-A7FC-4753-92F4-B4186979D147Q30879183-829C7CDC-2247-4EF1-894B-450B91946711Q33774580-0B29EF63-65A4-463B-9346-FAB46FB38564Q34360616-41E49F16-DF13-4911-B408-42884617DAF1Q34627879-AB5F12E2-5166-4A40-B506-1CD6269CAE04Q35763791-C010DCBA-8705-44B3-8884-9E8D179760FFQ36114898-257C2678-231C-4297-BECF-8F602EBAAEEDQ36115177-36DC1B38-7E26-4145-B8FC-6363F82D32C9Q36138631-E2DA2DF5-68EE-4924-B0FF-DE72A8D29B64Q36676608-390F5222-A935-4E91-9DDB-83C5F8753352Q37207397-9FCEC07F-6D99-4854-8102-E14D5EFBD99EQ38224605-9F022D4C-92E5-4A5E-8844-0B1A36996E89Q38243393-BA08B44E-1B71-437B-AAE8-FCFA4B03B276Q38302310-2FDAFDE0-4745-48F4-AB16-605AEA57A0ADQ39540046-6996C984-7285-47EC-B401-2D00038636D1Q40009288-553D22CF-1000-461F-BFBA-D58AA26A6C98Q40027360-7A2E6D9E-0645-4CC2-81A3-994CF2035345Q40202584-13D4E1B9-067E-401D-BB77-62B319E675F1Q40268466-D0EB8025-12BC-4753-9B2C-1D3F24E7D496Q40286264-A2726F1A-046C-4516-9513-DE4CC99E6D3EQ40375490-B722A73B-69D4-4786-B12B-C1A3D2547A17Q40682771-06243212-C615-4259-8C4D-73ADF679B979Q40729503-01A63F98-FB2E-4E4E-9BD4-74E74ED92A12Q40760681-F4F3B367-FF7F-48BC-A80B-B320D7607501Q41028756-F55255A7-40EF-47A5-95CF-F17BF4C5D834Q42053210-E53D6DCB-5D3D-4063-8026-AFC0F759D5CAQ42095382-8B5B2353-7A2E-4242-AD1E-D3567EE496E2Q42444180-CCB244F8-A50D-4520-B629-51F62C5D606DQ42450423-019E1115-F011-485A-8D5A-A6ABD1BDA477Q42520968-6AE3ED85-849A-4FE9-BDC3-0D1EE35DC174Q43732919-32F6B277-72F3-47C6-866E-0F53A353A48CQ45224424-12F70367-15A5-457F-A6CB-7C8489DEECBAQ48520992-D55F60B0-5C44-4EE4-8722-E78A42FBC4F1Q52206181-0840EA61-D46E-43AA-AFA0-576C98E7986DQ53000471-446E9256-8528-4D0D-A54B-EF0CF6FEE8CBQ53423509-7800323D-AA12-4BB9-9A78-367734E0EF0AQ53939274-9D765903-81F5-46FC-99BA-A9A0C90B64F7
P2860
Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Matrix metalloproteinase 9 exp ...... benign prostatic hyperplasia.
@en
Matrix metalloproteinase 9 exp ...... benign prostatic hyperplasia.
@nl
type
label
Matrix metalloproteinase 9 exp ...... benign prostatic hyperplasia.
@en
Matrix metalloproteinase 9 exp ...... benign prostatic hyperplasia.
@nl
prefLabel
Matrix metalloproteinase 9 exp ...... benign prostatic hyperplasia.
@en
Matrix metalloproteinase 9 exp ...... benign prostatic hyperplasia.
@nl
P2093
P2860
P356
P1476
Matrix metalloproteinase 9 exp ...... benign prostatic hyperplasia.
@en
P2093
Anderson JB
Silcocks PB
Thurrell W
Williams JL
P2860
P2888
P304
P356
10.1038/BJC.1994.30
P407
P577
1994-01-01T00:00:00Z